Amgen Q1 2025 results beat estimates with strong product growth. Stay updated on tariff risks and drug pricing impacts.

A federal jury in Delaware said on Thursday that biotech company Amgen owes competitor Regeneron more than $406 million for ...

In the long-running feud between Regeneron and Amgen around the companies’ competing PCSK9 cholesterol meds, Regeneron has eked out another legal win over its rival. A federal jury in Delaware ...

A federal jury in Delaware has awarded Regeneron (NASDAQ:REGN) more than $400M in damages after finding that Amgen (NASDAQ:AMGN) violated U.S. antitrust laws by forcing pharmacy benefit managers ...

Amgen prevented Regeneron from competing on a level playing field and unfairly denied patients access to Praluent. This anticompetitive practice shut out an innovative therapy from the PCSK9 ...

A jury found Amgen liable for antitrust violations, awarding Regeneron $406.8 million in damages related to Praluent competition. A federal court jury in Delaware has ruled that Amgen Inc ...

Last week, federal jurors in Delaware awarded Regeneron Pharmaceuticals Inc. more than $400 million in its antitrust showdown with Amgen Inc., the company’s rival in the market for cholesterol ...

We also discuss a new, tailored CRISPR treatment for an infant with a deadly disease, how Amgen owes Regeneron more than $400 million now, and more. From STAT’s Andrew Joseph: Lars Fruergaard ...

Federal court jury found Amgen liable for violating antitrust ... from competing in the market Jury awarded Regeneron $135.6 million dollars of compensatory damages and $271.2 million dollars ...